HomeCompareQTXB vs PFE

QTXB vs PFE: Dividend Comparison 2026

QTXB yields 400000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QTXB wins by $5.011119029548644e+32M in total portfolio value
10 years
QTXB
QTXB
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full QTXB calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — QTXB vs PFE

📍 QTXB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQTXBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QTXB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QTXB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QTXB
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, QTXB beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QTXB + PFE for your $10,000?

QTXB: 50%PFE: 50%
100% PFE50/50100% QTXB
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

QTXB
No analyst data
Altman Z
-14333.8
Piotroski
1/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QTXB buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQTXBPFE
Forward yield400000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$5.011119029548644e+32M$49.6K
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$5.010957816668433e+32M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QTXB vs PFE ($10,000, DRIP)

YearQTXB PortfolioQTXB Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$40,010,700$40,000,000.00$9,153$693.39+$40.00MQTXB
2$149,615,521,729$149,572,710,280.37$8,593$849.25+$149615.51MQTXB
3$522,880,052,725,200$522,719,964,116,949.25$8,336$1,066.78+$522880052.72MQTXB
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$8,437$1,384.80+$1707862989289.04MQTXB
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$9,013$1,875.40+$5213509402845684.00MQTXB
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$10,306$2,680.72+$14874219058409543680.00MQTXB
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$12,820$4,101.38+$3.966119623405075e+22MQTXB
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$17,673$6,826.70+$9.88384363503273e+25MQTXB
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$27,543$12,591.86+$2.302052364743449e+29MQTXB
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$49,560$26,258.71+$5.011119029548644e+32MQTXB

QTXB vs PFE: Complete Analysis 2026

QTXBStock

QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.

Full QTXB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this QTXB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QTXB vs SCHDQTXB vs JEPIQTXB vs OQTXB vs KOQTXB vs MAINQTXB vs JNJQTXB vs MRKQTXB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.